Safety of Intratracheal Administration of Human Umbilical Cord Blood Derived Mesenchymal Stromal Cells in Extremely Low Birth Weight Preterm Infants
- 1 July 2019
- journal article
- research article
- Published by Elsevier in The Journal of Pediatrics
- Vol. 210, 209-213.e2
Abstract
No abstract availableKeywords
Funding Information
- MediPost America
This publication has 36 references indexed in Scilit:
- Timing of Umbilical Cord Blood Derived Mesenchymal Stem Cells Transplantation Determines Therapeutic Efficacy in the Neonatal Hyperoxic Lung InjuryPLOS ONE, 2013
- Long-Term (Postnatal Day 70) Outcome and Safety of Intratracheal Transplantation of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Neonatal Hyperoxic Lung InjuryYonsei Medical Journal, 2013
- Mesenchymal Stem Cell‐Mediated Reversal of Bronchopulmonary Dysplasia and Associated Pulmonary HypertensionPulmonary Circulation, 2012
- The bioethics of stem cell research and therapyJournal of Clinical Investigation, 2010
- Bone Marrow Stromal Cells Attenuate Lung Injury in a Murine Model of Neonatal Chronic Lung DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Airway Delivery of Mesenchymal Stem Cells Prevents Arrested Alveolar Growth in Neonatal Lung Injury in RatsAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Fate and Effects of Adult Bone Marrow Cells in Lungs of Normoxic and Hyperoxic Newborn MiceAmerican Journal of Respiratory Cell and Molecular Biology, 2009
- Immunological properties of umbilical cord blood-derived mesenchymal stromal cellsCellular Immunology, 2008
- Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementCytotherapy, 2006
- Trypan Blue Exclusion Test of Cell ViabilityCurrent Protocols in Immunology, 1997